Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model.

The complexity of cancer signaling networks limits the efficacy of most single-agent treatments and brings about challenges in identifying effective combinatorial therapies. In this study, we used chronic active B-cell receptor (BCR) signaling in diffuse large B-cell lymphoma as a model system to establish a computational framework to optimize combinatorial therapy in silico We constructed a detailed kinetic model of the BCR signaling network, which captured the known complex cross-talk between the NFκB, ERK, and AKT pathways and multiple feedback loops. Combining this signaling model with a data-derived tumor growth model, we predicted viability responses of many single drug and drug combinations in agreement with experimental data. Under this framework, we exhaustively predicted and ranked the efficacy and synergism of all possible combinatorial inhibitions of eleven currently targetable kinases in the BCR signaling network. Ultimately, our work establishes a detailed kinetic model of the core BCR signaling network and provides the means to explore the large space of possible drug combinations. Cancer Res; 77(8); 1818-30. ©2017 AACR.

[1]  A. Tarakhovsky,et al.  PKCβ modulates antigen receptor signaling via regulation of Btk membrane localization , 2001, The EMBO journal.

[2]  Tilman Brummer,et al.  Feedback regulation of lymphocyte signalling , 2004, Nature Reviews Immunology.

[3]  J. Kutok,et al.  Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma , 2012, Clinical Cancer Research.

[4]  R. Lahesmaa,et al.  Capturing cell-fate decisions from the molecular signatures of a receptor-dependent signaling response , 2007, Molecular systems biology.

[5]  C. M. Cabrera,et al.  Identity tests: determination of cell line cross-contamination , 2006, Cytotechnology.

[6]  D. Krappmann,et al.  CARD-Bcl10-Malt1 Signalosomes: Missing Link to NF-κB , 2007, Science's STKE.

[7]  J. Andersen,et al.  Enzyme kinetic characterization of protein tyrosine phosphatases. , 2003, Biochimie.

[8]  M. Reth,et al.  Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop. , 2002, Molecular cell.

[9]  L. Staudt,et al.  Diffuse large B-cell lymphoma—treatment approaches in the molecular era , 2014, Nature Reviews Clinical Oncology.

[10]  John G Doench,et al.  SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. , 2013, Cancer cell.

[11]  T. Kurosaki,et al.  Protein kinase C mu (PKC mu) associates with the B cell antigen receptor complex and regulates lymphocyte signaling. , 1996, Immunity.

[12]  S. Rhee,et al.  Mechanism of B-Cell Receptor-Induced Phosphorylation and Activation of Phospholipase C-γ2 , 2004, Molecular and Cellular Biology.

[13]  Sam Michael,et al.  High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells , 2014, Proceedings of the National Academy of Sciences.

[14]  O. Elemento,et al.  Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies , 2014, Oncogene.

[15]  M. Reth,et al.  Syk is a dual-specificity kinase that self-regulates the signal output from the B-cell antigen receptor , 2010, Proceedings of the National Academy of Sciences.

[16]  H. Sanjo,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[17]  Dominik Wodarz,et al.  Tumor growth dynamics: insights into evolutionary processes. , 2013, Trends in ecology & evolution.

[18]  A. Weiss,et al.  Protein Kinase Cδ Promotes Transitional B Cell-Negative Selection and Limits Proximal B Cell Receptor Signaling To Enforce Tolerance , 2014, Molecular and Cellular Biology.

[19]  Jan Delabie,et al.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.

[20]  Lewis Luján Lm,et al.  Cell growth curves for different cell lines and their relationship with biological activities , 2013 .

[21]  Ali Mohammed,et al.  Effects of harvesting stage and storage duration on postharvest quality and shelf life of sweet bell pepper (Capsicum annuum L.) varieties under passive refrigeration system , 2013 .

[22]  Idan Tamir,et al.  Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy. , 2011, Immunity.

[23]  M. Baccarini,et al.  MEK1 Is Required for PTEN Membrane Recruitment, AKT Regulation, and the Maintenance of Peripheral Tolerance , 2013, Molecular cell.

[24]  G. Mills,et al.  Physical Association of PDK1 with AKT1 Is Sufficient for Pathway Activation Independent of Membrane Localization and Phosphatidylinositol 3 Kinase , 2010, PloS one.

[25]  Tara L. Naylor,et al.  Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. , 2011, Cancer research.

[26]  G. Lenz,et al.  Critical role of PI3K signaling for NF-κB–dependent survival in a subset of activated B-cell–like diffuse large B-cell lymphoma cells , 2010, Proceedings of the National Academy of Sciences.

[27]  H. Niiro,et al.  Decision making in the immune system: Regulation of B-cell fate by antigen-receptor signals , 2002, Nature Reviews Immunology.

[28]  R. Advani,et al.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Mariano J. Alvarez,et al.  Quantitative modeling of the terminal differentiation of B cells and mechanisms of lymphomagenesis , 2012, Proceedings of the National Academy of Sciences.

[30]  J. D. Dal Porto,et al.  B cell antigen receptor signaling 101. , 2004, Molecular immunology.

[31]  T. Kurosaki,et al.  BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. , 2000, Immunity.

[32]  Daniel C Kirouac,et al.  Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors , 2013, Science Signaling.

[33]  Doron Lancet,et al.  MOPED: Model Organism Protein Expression Database , 2011, Nucleic Acids Res..

[34]  R. Gascoyne,et al.  MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. , 2012, Cancer cell.

[35]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[36]  J. Kinet,et al.  BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity. , 2003, Immunity.

[37]  Sanjay Jain,et al.  Bistability in a model of early B cell receptor activation and its role in tonic signaling and system tunability. , 2013, Molecular bioSystems.

[38]  William W. Chen,et al.  Classic and contemporary approaches to modeling biochemical reactions. , 2010, Genes & development.

[39]  M. Fujimoto,et al.  CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. , 2000, Immunity.

[40]  S. Gauld,et al.  Src-family kinases in B-cell development and signaling , 2004, Oncogene.

[41]  L. Staudt,et al.  Targeting pathological B cell receptor signalling in lymphoid malignancies , 2013, Nature Reviews Drug Discovery.

[42]  Dipak Barua,et al.  A Computational Model for Early Events in B Cell Antigen Receptor Signaling: Analysis of the Roles of Lyn and Fyn , 2012, The Journal of Immunology.

[43]  G. Lenz,et al.  Malt1-dependent RelB cleavage promotes canonical NF-κB activation in lymphocytes and lymphoma cell lines , 2011, Proceedings of the National Academy of Sciences.

[44]  P. Marynen,et al.  T cell antigen receptor stimulation induces MALT1 paracaspase–mediated cleavage of the NF-κB inhibitor A20 , 2008, Nature Immunology.

[45]  James C. Stone,et al.  RasGRP1 and RasGRP3 Regulate B Cell Proliferation by Facilitating B Cell Receptor-Ras Signaling1 , 2005, The Journal of Immunology.

[46]  N. Varin‐Blank,et al.  Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma , 2013, Experimental Hematology & Oncology.

[47]  G. Packham,et al.  B-cell receptor signaling in chronic lymphocytic leukemia. , 2011, Blood.

[48]  Laurens P. Kil,et al.  Targeting Bruton's tyrosine kinase in B cell malignancies , 2014, Nature Reviews Cancer.

[49]  D. Krappmann,et al.  CARD-Bcl10-Malt1 signalosomes: missing link to NF-kappaB. , 2007, Science's STKE : signal transduction knowledge environment.

[50]  K. Moelling,et al.  Phosphorylation and regulation of Raf by Akt (protein kinase B). , 1999, Science.

[51]  D. Cantrell,et al.  Protein kinase C and beyond , 2004, Nature Immunology.